Last reviewed · How we verify
Spiriva HandiHaler
Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow.
Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.
At a glance
| Generic name | Spiriva HandiHaler |
|---|---|
| Also known as | LAMA |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Tiotropium is a selective M3 muscarinic receptor antagonist that prevents acetylcholine-induced bronchoconstriction. By blocking these receptors on airway smooth muscle, it produces sustained bronchodilation lasting 24 hours or longer. This reduces airway obstruction and improves lung function in chronic obstructive pulmonary disease (COPD) and asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment
Common side effects
- Dry mouth
- Tremor
- Headache
- Urinary retention
- Tachycardia
Key clinical trials
- Airway Effects of Tiotropium in Patients With COPD (PHASE3)
- Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (PHASE4)
- Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
- Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products (PHASE1)
- A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions (PHASE1)
- Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spiriva HandiHaler CI brief — competitive landscape report
- Spiriva HandiHaler updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI